Most dyslipidemic conditions have been linked to an increased risk of cardiovascular disease. Over the past few years major advances have been made regarding the genetic and metabolic basis of dyslipidemias. Detailed characterization of the genetic basis of familial lipid disorders and knowledge concerning the effects of environmental factors on the expression of dyslipidemias have increased substantially, contributing to a better diagnosis in individual patients. In addition to these developments, therapeutic options to lower cholesterol levels in clinical practice have expanded even further in patients with familial hypercholesterolemia and in subjects with cardiovascular disease. Finally, promising upcoming therapeutic lipid lowering strategies will be reviewed. All these advances will be discussed in relation to current clinical practice with special focus on common lipid disorders including familial dyslipidemias.

Additional Metadata
Keywords hypercholesterolemia, hyperlipidemia, lipid disorder, Lipoprotein, treatment
Persistent URL dx.doi.org/10.1016/j.cca.2018.09.010, hdl.handle.net/1765/110576
Journal Clinica Chimica Acta
Citation
Castro Cabezas, M, Burggraaf, B. (Benjamin), & Klop, B. (2018). Dyslipidemias in clinical practice. Clinica Chimica Acta (Vol. 487, pp. 117–125). doi:10.1016/j.cca.2018.09.010